Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cost of Revenue: 2021-2024

Historic Cost of Revenue for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Dec 2024 value amounting to $13.4 million.

  • Rhythm Pharmaceuticals' Cost of Revenue rose 43.65% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year increase of 44.18%. This contributed to the annual value of $13.4 million for FY2024, which is 43.71% up from last year.
  • As of FY2024, Rhythm Pharmaceuticals' Cost of Revenue stood at $13.4 million, which was up 43.71% from $9.3 million recorded in FY2023.
  • Rhythm Pharmaceuticals' Cost of Revenue's 5-year high stood at $13.4 million during FY2024, with a 5-year trough of $599,000 in FY2021.
  • Over the past 3 years, Rhythm Pharmaceuticals' median Cost of Revenue value was $9.3 million (recorded in 2023), while the average stood at $8.3 million.
  • Data for Rhythm Pharmaceuticals' Cost of Revenue shows a peak YoY surged of 336.10% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Rhythm Pharmaceuticals' Cost of Revenue stood at $599,000 in 2021, then skyrocketed by 256.09% to $2.1 million in 2022, then skyrocketed by 336.10% to $9.3 million in 2023, then surged by 43.71% to $13.4 million in 2024.